CSPC pharmaceutical reports revenue, profit decline in first nine months

CSPC Pharmaceutical Group Limited announced its unaudited consolidated results for the nine months ended 30 September 2025, revealing a 12.3% decrease in total revenue to RMB19,891,075 million compared to RMB22,686,151 million in the same period last year. Reported profit attributable to shareholders of the company also fell by 7.1% to RMB3,511,387 million. Basic earnings per share decreased by 4.1% to RMB30.72 cents.

The decline was primarily attributed to the finished drugs business, which saw a 17.2% decrease in revenue to RMB15,450,429 million, impacted by industry policies and price adjustments. However, bulk products revenue increased by 10.3% to RMB3,005,993 million, bolstered by a 22.3% rise in Vitamin C product sales due to increased overseas demand. Functional food and other businesses also grew by 11.2% to RMB1,434,653 million.

Underlying profit attributable to shareholders, a non-HKFRS measure, decreased by 23.0% to RMB3,078,615 million. This adjustment excludes fair value changes on financial assets (gain of RMB401,866 million) and a reversal of employee share-based compensation expense (RMB48,144 million). Research and development expenses increased by 7.9% to RMB4,185,010 million.